Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:56:34.790Z.
Calculation as of: 2026-10-06T16:56:34.790Z.
Quote observation: 2026-10-06T16:55:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e7bb4fe4bb3aa983eb4620adc8aa5d0f555a5020ff21ce65ee2b72f9631e0f85
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$2.81B
EV/EBITDA Ratio
27.18x
TTM Avg
35.89x
3Y Avg
85.56x
5Y Avg
85.56x
Market Cap
$2.68B
EV/EBITDA Ratio
9.49x
TTM Avg
8.14x
3Y Avg
8.61x
5Y Avg
8.66x
Market Cap
$2.67B
EV/EBITDA Ratio
13.17x
TTM Avg
11.53x
3Y Avg
20.03x
5Y Avg
19.21x
Market Cap
$2.67B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.65B
EV/EBITDA Ratio
32.49x
TTM Avg
28.10x
3Y Avg
22.56x
5Y Avg
30.37x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | $2.83B | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.81B | 27.18x | 35.89x | 85.56x | 85.56x |
| AtriCure, Inc. (ATRC)vs › | $2.79B | 77.42x | 85.01x | 85.01x | 85.01x |
| Precigen, Inc. (PGEN)vs › | $2.73B | N/A | N/A | N/A | N/A |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.68B | 9.49x | 8.14x | 8.61x | 8.66x |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.67B | 13.17x | 11.53x | 20.03x | 19.21x |
| MBX Biosciences, Inc. Common Stock (MBX)vs › | $2.67B | N/A | N/A | N/A | N/A |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.00B | N/A | N/A | N/A | N/A |
| Neogen Corporation (NEOG)vs › | $2.65B | 32.49x | 28.10x | 22.56x | 30.37x |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.03B | N/A | 9.21x | 9.21x | 9.21x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
